Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33(

קרןNational Cancer Institute/NIH
סוגResearch Grants
תאריך אחרון01/09/2023
פקולטהEngineering, Exact Sciences, Life Sciences, Medicine

This grant solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. 

R33 applications are sought where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.



Funding: $300,000 per year 

Duration: 3 years



Research Authority due date: 10 days prior to submission 

LOI (encouraged) due date: 1.2.23, 1.8.23

Full proposal due date: 1.3.23, 1.9.23



קבצים מצורפים
עדכון אחרוןעדכון אחרון: 04/12/2022
אוניברסיטת תל אביב עושה כל מאמץ לכבד זכויות יוצרים. אם בבעלותך זכויות יוצרים בתכנים שנמצאים פה ו/או השימוש
שנעשה בתכנים אלה לדעתך מפר זכויות, נא לפנות בהקדם לכתובת שכאן >>